Presentation at HealthBIO event, 15 September 2021

1. Orion’s new strategy and
industry trends seen
from a midsize pharma
perspective
Professor Antti Haapalinna, PhD, eMBA
Head of External Science and Partnering
Vice President, R&D

2. This presentation contains forward-looking statements which involve risks and uncertainty
factors. These statements are not based on historical facts but relate to the Company’s future
activities and performance. They include statements about future strategies and anticipated
benefits of these strategies.
These statements are subject to risks and uncertainties. Actual results may differ
substantially from those stated in any forward-looking statement. This is due to a number of
factors, including the possibility that Orion may decide not to implement these strategies and
the possibility that the anticipated benefits of implemented strategies are not achieved.
Orion assumes no obligation to update or revise any information included in this presentation.
Disclaimer
2

3. Agenda
3
1. Orion in brief 2. Industry trends? 3. Orion’s strategy

4. Orion in Brief

5. Orion at a glance (2020 figures)
Orion Corporation Presentation
Net sales
Operating profit
Personnel
R&D investments
6 production sites in Finland
Own sales unit in 26 European countries,
Singapore, Malaysia, Thailand and Australia
1,078 MEUR
280 MEUR
3,311
123 MEUR
Established in 1917
5
Orion has operations in 30 countries (Europe and Asia)

6. Proprietary Products Specialty Products Animal Health
Fermion & Contract
manufacturing
June 2021 Orion Corporation Presentation 6
Orion’s businesses
350
351
357
406
444
2016 2017 2018 2019 2020
Net
sales
MEUR
508
519
473
486
493
2016 2017 2018 2019 2020
Net
sales
MEUR
77
76
80
86
89
2016 2017 2018 2019 2020
Net
sales
MEUR
81
84
65
71
74
2016 2017 2018 2019 2020
Net
sales
MEUR
39% 46% 8% 7%
= share of Group net sales in 2020
In-house developed drugs
and other drugs with valid
product protection for global
markets. Own sales network
in Europe.
Generic prescription drugs,
OTC and non-medicinal
products, biosimilars.
Finland 56%
Scandinavia 16%
Eastern Europe 14%
ROW 14%
Own animal drugs for global
markets. Other drugs and
well-being products. Own
sales network in the Nordics
and Eastern Europe.
Active pharmaceutical
ingredients (APIs) for own
proprietary products. CMO &
CDMO services for other
pharma companies.

7. What are the pharmaceutical industry trends?

8. 13
September
2021
Presenter / Department 8
Consumer
• Population aging
• Health awareness intensifying
• Demand for personalised therapy increasing, big
disease will be fragmented (Precision medicine)
• Service concepts broadening
• New distribution channels emerging
• Private spend on medicines increasing
Technology
• R&D productivity more challenging
• Role of biologicals has increased
• Alternative technologies emerging (paradigm shift from
managing diseases to curing diseases. Curative therapies such as
cell and gene therapies)
• Digitalization /E-commerce opportunities broadening
(AI, Real-world data, Real-world evidence, Digital therapeutics...)
World has become and is becoming more complex ...

9. 13
September
2021
Presenter / Department 9
Socio-economic
• Economic downturn still influencing
• Role of innovations as growth driver
increasing
• Number of generic launches increasing
• Growth in emerging markets increasing
• Competition intensifying
• Numerous market specific payer actions emerging
Regulatory
• Price regulations increasing
• Reimbursement requirements increasing
• Scrutiny on drug efficacy and safety intensifying
• Time span of regulatory processes extending
World has become and is becoming more complex ...

10. 13
September
2021
Presenter / Department 10

11. 11
Challenges
• Obsolescence of current products and services
• Traditional business models become outdated
• Devaluation of current organizational
capabilities
• New, unknown or unexpected competitors
Opportunities
• New levels of engagement with customers (sales
vs customer data)
• More valuable relationships – contribution to
societies
• New creative partnerships and alliances
Medicine as a service

12. 12

13. Orion’s strategy

14. Strategic growth target: Net sales EUR 1.5 billion in 2025
Financial objectives:

Growing net sales more rapidly
than growth of the pharma market.
Achievement of this objective
requires continuous investment in
development of the product
portfolio.
≥ Keeping the equity ratio at
least 50%.
>
Maintaining profitability at a good
level. The aim is operating profit
that exceeds 25% of net sales. €
Distributing an annual dividend that
in the next few years will be at least
EUR 1.30 per share, and increasing
the dividend in the long term.
Orion’s strategic growth target and financial objectives
Investor Presentation © Orion Corporation

15. Deliver late-stage
portfolio
Build
portfolio
Maximize value
of assets
R&D- Translating world-class science into novel life-changing therapies
Our mission is to make new medicines for the patients with
unmet need Building the growth for Orion
15
- Invent and find the medicinal
targets and molecules and develop
them as medicines to humans and
animals
- Look collaborations and partner
ships for new technologies
Get marketing
authorizations for the
developed products and
globally together with
partners
Support the growth of marketed
products in new territories and with
additional studies
Compliance and availability of
products on the markets

16. 16
Key changes in Orion R&D
1
2 4
1 Research
strengthened to
drive target
identification
and validation
2
Resources re-
allocated for
the prioritized
projects
3
Focused clinical
trials on
biomarker
selected
patients
4
Support pipeline
with in-licensing
and partnering
5
Boosting
generics
development
6
Microbiome
research in
Animal Health
Science & Data driven organisation
• Focused strategy in Oncology
and Neurological Diseases
Build a balanced
pipeline with
continuous feed of
clinical projects
Increase
success rate
and speed
AREAS TO DEVELOP
R&D- Translating world-class science into novel life-changing therapies

17. 17
Orion Corporation signs European wide marketing and distribution agreement
with Marinus Pharmaceuticals for ganaxolone
PRESS RELEASE 3 AUGUST 2021
https://www.orion.fi/en/Orion-group/media/press-releases/2021/orion-corporation-signs-european-wide-marketing-and-distribution-agreement-with-marinus-pharmaceuticals-for-ganaxolone/?epieditmode=true
Orion’s Clinical Trial Shows Significant Improvement for Chronic Pain Patients Using
Virtual Reality Therapy
PRESS RELEASE 9 JUNE 2021
https://www.orion.fi/en/Orion-group/media/press-releases/2021/orions-clinical-trial-shows-significant-improvement-for-chronic-pain-patients-using-virtual-reality-therapy/?epieditmode=true
Orion Animal Health’s Tessie® (tasipimidine) receives positive CVMP opinion
PRESS RELEASE 21 JUNE 2021
https://www.orion.fi/en/Orion-group/media/press-releases/2021/orion-animal-healths-tessie-tasipimidine-receives-positive-cvmp-opinion/?epieditmode=true
A few public examples of this year
R&D- Translating world-class science into novel life-changing therapies

18. 18
Chimeric Antigen Receptor T-cell therapy as
an example of personalised therapy
Three approved CAR T-cell
therapies with excellent
response rates for
hematological cancers
Gene manipulated
cells is the Product
R&D- Translating world-class science into novel life-changing therapies

19. 19
Orion Corporation and the Finnish Red Cross Blood
Service have concluded an agreement on research
collaboration with the aim of developing chimeric
antigen receptor (CAR) T-cell therapy
https://www.orion.fi/en/Orion-group/media/press-releases/2021/-orion-and-the-blood-service-launch-collaboration-to-develop-new-car-t-cell-cancer-therapy/?epieditmode=true
PRESS RELEASE 8 JUNE 2021
The Blood Service has
considerable experience in cell
research, in the supply of cord
blood and stem cell grafts
classified as tissue products, and
in the preparation of ATMP cell
products classified as medicinal
products. The Blood Service also
has expertise and the necessary
clean rooms for the research and
high-quality production of
therapeutic cells.
R&D- Translating world-class science into novel life-changing therapies

20. 20
Orion Corporation and Alligator Bioscience announce
immuno-oncology research collaboration and license
agreement
PRESS RELEASE 18 AUGUST 2021
https://www.orion.fi/en/Orion-group/media/press-releases/2021/orion-corporation-and-alligator-bioscience-announce-immuno-oncology-research-collaboration-and-license-agreement/
Fig from: Huang, S., van Duijnhoven, S.M.J., Sijts, A.J.A.M. et al. Bispecific antibodies targeting dual tumor-associated antigens
in cancer therapy. J Cancer Res Clin Oncol 146, 3111–3122 (2020)
Bispecific antibody will be developed based
on the Alligator's proprietary bispecific
antibody format
Alligator’s role is to design, generate and
ensure good quality of antibodies
Orion’s role is in vitro and in vivo
characterization to enable candidate
nomination, clinical development by Orion
Bispecific antibodies provide as a tool
many advantages for the next generation
immuno-oncology treatments with
improved efficacy, particularly in the
cancer patients who do not respond to the
present available therapeutic
R&D- Translating world-class science into novel life-changing therapies

21. 21
To be successful now and in the future
Exploit
- Deliver portfolio
- Maximize value
of assets
Explore
- Build portfolio
and new services
- New Partnerships
- New Technologies
- New ecosystems
At the same time is needed:
* Focused strategy * Innovation and creativity
* Goal directed actions * Acceptance of changes
* Cost effectiveness * Tolerance for failures